134 related articles for article (PubMed ID: 37990895)
1. Nanoparticles Containing Oxaliplatin and the Treatment of Colorectal Cancer.
Mahaki H; Mansourian M; Meshkat Z; Avan A; Shafiee MH; Mahmoudian RA; Ghorbani E; Ferns GA; Manoochehri H; Menbari S; Sheykhhasan M; Tanzadehpanah H
Curr Pharm Des; 2023; 29(38):3018-3039. PubMed ID: 37990895
[TBL] [Abstract][Full Text] [Related]
2. Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer.
Du W; Yang X; He S; Wang J; Guo Y; Kou B; Jiang Y; Bian P; Li B; Yin L
Drug Deliv; 2021 Dec; 28(1):920-929. PubMed ID: 33974471
[TBL] [Abstract][Full Text] [Related]
3. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
4. Improved anti-colorectal carcinomatosis effect of tannic acid co-loaded with oxaliplatin in nanoparticles encapsulated in thermosensitive hydrogel.
Ren Y; Li X; Han B; Zhao N; Mu M; Wang C; Du Y; Wang Y; Tong A; Liu Y; Zhou L; You C; Guo G
Eur J Pharm Sci; 2019 Feb; 128():279-289. PubMed ID: 30553061
[TBL] [Abstract][Full Text] [Related]
5. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Gao R; Fang C; Xu J; Tan H; Li P; Ma L
Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
[TBL] [Abstract][Full Text] [Related]
6. Maximizing the potency of oxaliplatin coated nanoparticles with folic acid for modulating tumor progression in colorectal cancer.
Oliveira ALCSL; Zerillo L; Cruz LJ; Schomann T; Chan AB; de Carvalho TG; Souza SVP; Araújo AA; de Geus-Oei LF; de Araújo Júnior RF
Mater Sci Eng C Mater Biol Appl; 2021 Jan; 120():111678. PubMed ID: 33545840
[TBL] [Abstract][Full Text] [Related]
7. Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma.
Zumaya ALV; Rimpelová S; Štějdířová M; Ulbrich P; Vilčáková J; Hassouna F
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163122
[TBL] [Abstract][Full Text] [Related]
8. Dichotomic Role of Low-Concentration EGCG in the Oxaliplatin Sensitivity of Colorectal Cancer Cells.
Wang Z; Wang M; Huang J; Lin M; Wei P
Dokl Biochem Biophys; 2024 Apr; 515(1):29-35. PubMed ID: 38189882
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach.
Zhang Z; Lu T; Zhang Z; Liu Z; Qian R; Qi R; Zhou F; Li M
Biochem Pharmacol; 2024 Apr; 222():116117. PubMed ID: 38461903
[TBL] [Abstract][Full Text] [Related]
10. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells.
Zhang Z; Shen C; Zhou F; Zhang Y
Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379
[TBL] [Abstract][Full Text] [Related]
11. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
[TBL] [Abstract][Full Text] [Related]
12. XPF-ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer.
Huang MY; Huang YJ; Cheng TL; Jhang WY; Ke CC; Chen YT; Kuo SH; Lin IL; Huang YH; Chuang CH
Cells; 2023 May; 12(11):. PubMed ID: 37296596
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin derived monofunctional triazole-containing platinum(II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer.
Li Y; Sun Z; Cui Y; Zhang H; Zhang S; Wang X; Liu S; Gao Q
Bioorg Chem; 2021 Feb; 107():104636. PubMed ID: 33465670
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.
Wang K; Liu L; Zhang T; Zhu YL; Qiu F; Wu XG; Wang XL; Hu FQ; Huang J
Int J Nanomedicine; 2011; 6():3207-18. PubMed ID: 22238509
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNAs: Key regulators in oxaliplatin resistance of colorectal cancer.
Qi FF; Yang Y; Zhang H; Chen H
Biomed Pharmacother; 2020 Aug; 128():110329. PubMed ID: 32502843
[TBL] [Abstract][Full Text] [Related]
16. Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.
Wei TT; Lin YT; Tang SP; Luo CK; Tsai CT; Shun CT; Chen CC
Oncogene; 2020 Jan; 39(2):414-427. PubMed ID: 31477841
[TBL] [Abstract][Full Text] [Related]
17. Tumor RNA-loaded nanoliposomes increases the anti-tumor immune response in colorectal cancer.
Dai D; Yin Y; Hu Y; Lu Y; Zou H; Lu G; Wang Q; Lian J; Gao J; Shen X
Drug Deliv; 2021 Dec; 28(1):1548-1561. PubMed ID: 34286631
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Kalofonos HP
J Peripher Nerv Syst; 2021 Mar; 26(1):43-48. PubMed ID: 33345432
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid oligosaccharide-modified zeolitic imidazolate framework-8 nanoparticles loaded with oxaliplatin as a targeted drug-delivery system for colorectal cancer therapy.
Li B; Zhang Z; He S; Du W; Yang X; Kou B; Jiang Y; Bian P; Yin L
Nanomedicine (Lond); 2023 May; 18(12):891-905. PubMed ID: 37409459
[No Abstract] [Full Text] [Related]
20. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
